Eupraxia Pharmaceuticals Inc

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell and John Salvatore Montalbano on May 12, 2011 and is headquartered in Victoria, Canada.

VICTORIA, BC , Sept. 19, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the upcoming 20th International Symposium on Digestive Endoscopy ("ISDE") World Congress for Esophageal Diseases to be held in Edinburgh, Scotland on September 22-24, 2024.

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks The fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to date The RESOLVE Phase 1b/2a trial is progressing as anticipated with no serious adverse events reported in all four fully-dosed cohorts VICTORIA, BC , Sept. 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE").

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

VICTORIA, BC , Sept. 4, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting at the upcoming H.C.

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

VICTORIA, BC , Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

The Company also provides an update on the Silicon Valley Bank convertible debt facility Including the new C$12 million convertible debt facility, Eupraxia anticipates it has sufficient cash to fund its operations to the second quarter of 2025 VICTORIA, BC , Aug. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced entry into a new C$12 million convertible debt facility (the "Convertible Debt Facility"). Under the Convertible Debt Facility, Yabema Capital Limited and other current Eupraxia shareholders (together, the "Lenders") will make available for drawdown an aggregate amount of C$12 million for a period of 120 days following entry into the agreement.

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

VICTORIA, BC , July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company's Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the upcoming Controlled Release Society 2024 Annual Meeting and Expo being held in Bologna, Italy from July 8-12, 2024. Presentation Details: Abstract ID:                        4085079 Presentation Title:            EP-104, a novel microparticle formulation achieving extended-release of fluticasone propionate Session Type:                    Oral Abstract Presentation Session Title:                      Long-Acting Drug Delivery Formulations - Session #2 Session Date & Time:      July 10, 2024, from 9:00 AM to 11:00 AM CEST (3:00 AM to 5:00 AM ET) The presentation will also be available on Eupraxia's website at: https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx.

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. alone.

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

VICTORIA, BC , June 6, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 6, 2024. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the "Board") at the Meeting and listed in the Company's Management Information Circular dated May 1, 2024, were elected.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology ("EULAR") European Congress of Rheumatology 2024 (the "Meeting"). The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024.

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansion Early low-dose cohorts showing meaningful improvement in patient symptoms and biological evidence of disease Trial expansion allows more patients to be treated at higher doses and followed for up to 52 weeks, up from 24 weeks VICTORIA, BC , May 23, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that regulators in Australia and Canada have cleared the Company's request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). The recently disclosed clinical data from initial low-dose cohorts showing signs of potential efficacy, as well as encouraging safety and duration of impact from EP-104GI, support the significant expansion of the RESOLVE trial as a pathway to a potential registration trial commencing in 2025.

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

VICTORIA, BC , May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, May 29, 2024, at 10:00 AM ET. To register, please click here.

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks Data from  the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohort Data from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeks EP-104GI showed an encouraging safety profile in all three cohorts VICTORIA, BC , May 21, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). "New data from the RESOLVE trial's first and second cohorts showed good tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects," said Dr. James Helliwell, Chief Executive Officer of Eupraxia.

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

VICTORIA, BC , May 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week ("DDW") Annual Meeting 2024. The meeting is being held in Washington, D.C.

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia common shares now listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "EPRX" Additional data from RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE") expected in the second quarter of 2024 Annual general and special meeting scheduled for June 6, 2024 VICTORIA, BC , May 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2024 and provided a corporate update. "The first quarter of 2024 was a highly productive period for Eupraxia, with our team achieving multiple clinical and corporate milestones," said Dr. James Helliwell, CEO of Eupraxia.

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

--Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program--  VICTORIA, BC , May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw.

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

VICTORIA, BC , April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

VICTORIA, BC , April 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Eupraxia CEO Dr. James Helliwell will present on April 16th, 2024, at 10:30 am ET at the Metro Toronto Convention Centre, and will participate in investor meetings at the conference on April 16th and 17th.

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

VICTORIA, BC , April 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that trading of the Company's common shares will begin today, April 5, 2024, on the Nasdaq Capital Market ("Nasdaq"), under the ticker symbol "EPRX". The Company's shares also continue to trade on the Toronto Stock Exchange under the ticker symbol "EPRX".

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

Company's Listing Application Approved by Nasdaq VICTORIA, BC , April 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq Capital Market ("Nasdaq"). The Company's shares are expected to begin trading on Nasdaq on April 5, 2024, under the ticker symbol "EPRX".

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

VICTORIA, BC , April 1, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All amounts are expressed in U.S. dollars unless otherwise indicated.

News for Eupraxia Pharmaceuticals Inc Stock (EPRX)